* women who are pregnant (at the time of screening) or breastfeeding * known hypersensitivity or allergy to hydroxychloroquine or other aminoquinoline compounds * history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis * history of pre-existing retinopathy or maculopathy, * concomitant use of tamoxifen * history of congenital or acquired long qt-interval, current use of drugs that prolong the qt interval, * family history of long qt arrythmia, cardiac disease such as heart failure, myocardial infarction * concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death, or sudden cardiac death, bradycardia \< 50 beats/min, uncorrected hypokalemia or hypomagnesemia * severe renal disease or patients receiving dialysis * patients less than 35 kg bodyweight * currently taking hydroxychloroquine * suspected or confirmed current covid-19, defined as: (1) temperature \> 38 celsius; (2) cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5) positive confirmatory testing for covid-19 * inability to take medications orally * inability to provide written consent * with significantly abnormal liver function * participants with psoriasis, myasthenia, hematopoietic and retinal diseases, cns-related hearing loss; * rt-pcr positive for sars-cov-2, igm and igg antibodies for sars-cov-2 * currently using another treatment regimen or medication that is being investigated for efficacy in the management of covid-19.

* women who are pregnant (at the time of screening) or breastfeeding * known hypersensitivity or allergy to hydroxychloroquine or other aminoquinoline compounds * history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis * history of pre-existing retinopathy or maculopathy, * concomitant use of tamoxifen * history of congenital or acquired long qt-interval, current use of drugs that prolong the qt interval, * family history of long qt arrythmia, cardiac disease such as heart failure, myocardial infarction * concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death, or sudden cardiac death, bradycardia \< 50 beats/min, uncorrected hypokalemia or hypomagnesemia * severe renal disease or patients receiving dialysis * patients less than 35 kg bodyweight * currently taking hydroxychloroquine * suspected or confirmed current covid-19, defined as: (1) temperature \> 38 celsius; (2) cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5) positive confirmatory testing for covid-19 * inability to take medications orally * inability to provide written consent * with significantly abnormal liver function * participants with psoriasis, myasthenia, hematopoietic and retinal diseases, cns-related hearing loss; * rt-pcr positive for sars-cov-2, igm and igg antibodies for sars-cov-2 * currently using another treatment regimen or medication that is being investigated for efficacy in the management of covid-19.

- women who are pregnant (at the time of screening) or breastfeeding - known hypersensitivity or allergy to hydroxychloroquine or other aminoquinoline compounds - history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis - history of pre-existing retinopathy or maculopathy, - concomitant use of tamoxifen - history of congenital or acquired long qt-interval, current use of drugs that prolong the qt interval, - family history of long qt arrythmia, cardiac disease such as heart failure, myocardial infarction - concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death, or sudden cardiac death, bradycardia < 50 beats/min, uncorrected hypokalemia or hypomagnesemia - severe renal disease or patients receiving dialysis - patients less than 35 kg bodyweight - currently taking hydroxychloroquine - suspected or confirmed current covid-19, defined as: (1) temperature > 38 celsius; (2) cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5) positive confirmatory testing for covid-19 - inability to take medications orally - inability to provide written consent - with significantly abnormal liver function - participants with psoriasis, myasthenia, hematopoietic and retinal diseases, cns-related hearing loss; - rt-pcr positive for sars-cov-2, igm and igg antibodies for sars-cov-2 - currently using another treatment regimen or medication that is being investigated for efficacy in the management of covid-19.

- women who are pregnant (at the time of screening) or breastfeeding - known hypersensitivity or allergy to hydroxychloroquine or other aminoquinoline compounds - history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis - history of pre-existing retinopathy or maculopathy, - concomitant use of tamoxifen - history of congenital or acquired long qt-interval, current use of drugs that prolong the qt interval, - family history of long qt arrythmia, cardiac disease such as heart failure, myocardial infarction - concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death, or sudden cardiac death, bradycardia < 50 beats/min, uncorrected hypokalemia or hypomagnesemia - severe renal disease or patients receiving dialysis - patients less than 35 kg bodyweight - currently taking hydroxychloroquine - suspected or confirmed current covid-19, defined as: (1) temperature > 38 celsius; (2) cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5) positive confirmatory testing for covid-19 - inability to take medications orally - inability to provide written consent - with significantly abnormal liver function - participants with psoriasis, myasthenia, hematopoietic and retinal diseases, cns-related hearing loss; - rt-pcr positive for sars-cov-2, igm and igg antibodies for sars-cov-2 - currently using another treatment regimen or medication that is being investigated for efficacy in the management of covid-19.